Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2012 Jan 10;9(2):74-6. doi: 10.1038/nrclinonc.2011.201.

Melanoma in 2011: a new paradigm tumor for drug development.

Author information

1
Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, Paris-Sud, France. alexander.eggermont@igr.fr

Abstract

Melanoma has emerged as the paradigm tumor for drug development through mutation-targeted therapies (inhibitors targeting BRAF, MEK, and c-KIT) and immunotherapy. Exploring the combinations of both approaches is a challenge that will require scientific rationale and the cooperation of the pharmaceutical industry. But, with these challenges comes another opportunity to change the paradigms in drug development.

PMID:
22231762
DOI:
10.1038/nrclinonc.2011.201
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center